ACEL vs THRM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACEL's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While the company shows strong earnings growth and beats earnings estimates consistently, high leverage (Debt/Equity: 2.22) and weak insider sentiment counterbalance these positives. Valuation is mixed—trading below analyst target of $15.17 but above the conservative Graham Number of $5.93. The stock faces headwinds from recent price underperformance and insider selling, despite solid ROE and revenue momentum.
THRM presents a contradictory profile: a stable balance sheet paired with deteriorating earnings performance. The Piotroski F-Score of 4/9 indicates stable but mediocre financial health, while the current price of $29.58 trades at a significant premium to both the Graham Number ($17.7) and the growth-based Intrinsic Value ($4.13). While the Forward P/E of 9.58 suggests a massive expected earnings recovery, the current YoY earnings crash of -81.20% and a bearish technical trend create significant near-term risk. The investment thesis relies entirely on a turnaround in profitability that has not yet materialized in the data.
Compare Another Pair
Related Comparisons
ACEL vs THRM: Head-to-Head Comparison
This page compares Accel Entertainment, Inc. (ACEL) and Gentherm Incorporated (THRM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.